About OptiNose (NASDAQ:OPTN)
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-4.23
Forward P/E Ratio-7.57
Sales & Book Value
Annual Sales$47.50 million
Price / Sales19.08
Price / CashN/A
Book Value$4.09 per share
Price / Book5.83
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
OptiNose (NASDAQ:OPTN) Frequently Asked Questions
What is OptiNose's stock symbol?
OptiNose trades on the NASDAQ under the ticker symbol "OPTN."
How were OptiNose's earnings last quarter?
OptiNose Inc (NASDAQ:OPTN) issued its quarterly earnings results on Monday, May, 14th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.74) by $0.07. The firm earned $0.87 million during the quarter. View OptiNose's Earnings History.
What price target have analysts set for OPTN?
4 Wall Street analysts have issued 1 year price objectives for OptiNose's shares. Their predictions range from $27.00 to $33.00. On average, they anticipate OptiNose's stock price to reach $29.25 in the next year. View Analyst Ratings for OptiNose.
Who are some of OptiNose's key competitors?
Some companies that are related to OptiNose include Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Portola Pharmaceuticals (PTLA), Emergent Biosolutions (EBS), Evotec (EVTCY), OPKO Health (OPK), Intercept Pharmaceuticals (ICPT), Arena Pharmaceuticals (ARNA), Clovis Oncology (CLVS) and Xencor (XNCR).
Who are OptiNose's key executives?
OptiNose's management team includes the folowing people:
- Mr. Peter K. Miller, CEO & Director (Age 57)
- Dr. Ramy A. Mahmoud M.D., M.P.H., Pres& COO (Age 53)
- Mr. Keith Alan Goldan, Chief Financial Officer (Age 47)
- Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 42)
- Mr. Thomas E. Gibbs, Chief Commercial Officer (Age 46)
When did OptiNose IPO?
(OPTN) raised $101 million in an initial public offering on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.
Has OptiNose been receiving favorable news coverage?
Media coverage about OPTN stock has trended somewhat positive on Sunday, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. OptiNose earned a news sentiment score of 0.15 on Accern's scale. They also assigned news articles about the company an impact score of 46.46 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are OptiNose's major shareholders?
OptiNose's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (1.83%), Foresite Capital Management IV LLC (1.28%), Asymmetry Capital Management L.P. (0.89%), Next Century Growth Investors LLC (0.41%), American Century Companies Inc. (0.28%) and Neuberger Berman Group LLC (0.26%). Company insiders that own OptiNose stock include Peter K Miller, Robert P O'neil and Sriram Venkataraman. View Institutional Ownership Trends for OptiNose.
Which major investors are selling OptiNose stock?
Which major investors are buying OptiNose stock?
OPTN stock was bought by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Tamarack Advisers LP, Next Century Growth Investors LLC, Asymmetry Capital Management L.P., Foresite Capital Management IV LLC, American Century Companies Inc. and Northern Trust Corp. Company insiders that have bought OptiNose stock in the last two years include Peter K Miller and Robert P O'neil. View Insider Buying and Selling for OptiNose.
How do I buy shares of OptiNose?
Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OptiNose's stock price today?
One share of OPTN stock can currently be purchased for approximately $23.84.
How big of a company is OptiNose?
OptiNose has a market capitalization of $906.09 million and generates $47.50 million in revenue each year. The company earns $-48,900,000.00 in net income (profit) each year or ($5.63) on an earnings per share basis. OptiNose employs 82 workers across the globe.
How can I contact OptiNose?
OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]
MarketBeat Community Rating for OptiNose (OPTN)MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote "Outperform" if you believe OPTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days.